14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CNCE ranks #15427 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Concert Pharmaceuticals Stock Forecast NASDAQ:CNCE

$2.88 (-2.37%)

Volume: 59k

Closed: Oct 15, 2021

Hollow Logo Score: -3.104

Concert Pharmaceuticals Stock Forecast

$2.88 (-2.37%)

Volume: 59k

Closed: Oct 15, 2021

Score Hollow Logo -3.104
Which way will CNCE go? Request
Earnings Date: Nov 03, 2021
Key Stats
Beta 0.66
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 25 and the stock is currently not being overbought or oversold

Concert Pharmaceuticals stock price down 2.37% on Friday
(Updated on Oct 15, 2021)

Sell candidate since 2021-09-23 Loss -15.79%

The Concert Pharmaceuticals stock price fell by -2.37% on the last day (Friday, 15th Oct 2021) from $2.95 to $2.88. and has now fallen 3 days in a row. During the day the stock fluctuated 3.50% from a day low at $2.86 to a day high of $2.96. The price has fallen in 7 of the last 10 days and is down by -10.56% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -6 thousand shares and in total, 59 thousand shares were bought and sold for approximately $170.90 thousand.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $2.83 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -9.57% during the next 3 months and, with a 90% probability hold a price between $2.56 and $3.26 at the end of this 3-month period.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Tuesday, October 12, 2021, and so far it has risen 1.05%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Concert Pharmaceuticals stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $2.94 and $3.33. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss

Concert Pharmaceuticals finds support from accumulated volume at $2.85 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.10 between high and low, or 3.50%. For the last week the stock has had a daily average volatility of 5.08%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Concert Pharmaceuticals stock A Buy?

Concert Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -3.104

Predicted Opening Price for Concert Pharmaceuticals of Monday, October 18, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price October 18, 2021 Current price
$2.90 $2.88 (Undervalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Oct 05, 2021 "Mizuho" gave "$13.00 - $9.00" rating for CNCE. The price target was changed from $3.03 to 3.5%.

Volatility and Risk
Daily Average Volatility: 5.08 %
Overall Risk: Very High High Medium Low Very Low
5.08 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $3.31
Price: $2.88
Support: $2.85

CNCE Insider Trading Show all Trades



Last 100 transactions
Buy: 2 056 315 | Sell: 628 336 (Shares)
Date Action Amount Person Type
Aug 16, 2021 Sell 7 304 Becker Marc A. Common Stock
Aug 16, 2021 Sell 8 086 Cassella James V Common Stock
Jun 10, 2021 Buy 5 125 Aldrich Richard Common Stock
Jun 10, 2021 Buy 10 250 Aldrich Richard Stock Option (right to buy)
Jun 10, 2021 Buy 30 182 Aldrich Richard Stock Option (right to buy)
Show all Insider Trades


Last 100 transactions
Buy: 2 056 315 | Sell: 628 336 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 3.00 4.17 %
2.96 2.84 %
2.94 2.02 %
Current price: 2.88
Support 2.86 -0.63 %
2.84 -1.45 %
2.80 -2.78 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 3.37 17.01 %
3.33 15.63 %
3.31 14.93 %
Current price 2.88
Support 2.85 -1.04%
0 .
0 .

Click to get the best stock tips daily for free!

About Concert Pharmaceuticals

Concert Pharmaceuticals Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for genetic diseases, inflammatory disease, and neurologic disorders. The company’s clinical-stage product candidates include AVP-786, which is in Phase 2 and Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including Alzheimer’s agitation, depressive disorders, and residual schizophrenia; and ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE